Simeglutide Injection is relatively safe when used as prescribed, but there are some adverse effects. The drug is a new long-acting glucagon-like peptide-1 (GLP-1) analog that is primarily used in the treatment of type 2 diabetes. Adverse effects present with this drug include hypoglycemia, gastrointestinal adverse effects, acute pancreatitis, rash or erythema at the injection site, increased heart rate, and acute kidney damage. The drug has also been found to have a risk of causing C-cell tumors of the thyroid in rodents in animal studies, and the relevance to humans has not yet been determined. Simeglutide Injection should not be used in patients with type 1 diabetes mellitus or in the treatment of diabetic ketoacidosis, and is contraindicated in patients with a personal past history or family history of medullary thyroid carcinoma, and in patients with multiple endocrine neoplasia syndrome type 2. If there is any discomfort during the use of this drug, it is recommended to visit the hospital in time for treatment with the help of a doctor.